PortfoliosLab logo
Quoin Pharmaceuticals Ltd DRC (QNRX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US74907L1026

IPO Date

Jul 29, 2016

Highlights

Market Cap

$5.23M

EPS (TTM)

-$34.62

Gross Profit (TTM)

-$24.91K

EBITDA (TTM)

-$7.00M

Year Range

$5.01 - $37.80

Target Price

$156.80

Short %

14.52%

Short Ratio

0.06

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Quoin Pharmaceuticals Ltd DRC

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

Quoin Pharmaceuticals Ltd DRC (QNRX) returned -56.73% year-to-date (YTD) and -61.93% over the past 12 months.


QNRX

YTD

-56.73%

1M

38.54%

6M

-53.05%

1Y

-61.93%

3Y*

-85.63%

5Y*

-82.57%

10Y*

N/A

^GSPC (Benchmark)

YTD

0.68%

1M

7.17%

6M

-1.66%

1Y

11.63%

3Y*

12.51%

5Y*

14.34%

10Y*

10.88%

*Annualized

Monthly Returns

The table below presents the monthly returns of QNRX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-48.85%-6.61%-27.97%-13.66%45.66%-56.73%
2024-27.22%-22.97%-65.45%-25.47%9.75%-25.35%3.45%4.33%-21.25%51.52%-19.68%8.50%-86.73%
202317.61%-65.87%-16.49%5.04%-14.80%17.37%31.17%-26.94%-27.83%-1.93%22.19%-1.37%-71.21%
2022-23.63%-20.14%19.82%-39.77%-20.72%-29.13%-20.67%-26.72%-31.80%-17.04%-9.73%-14.97%-93.76%
202133.33%15.97%-5.99%-19.75%24.21%19.81%13.87%24.12%-12.92%-36.94%-67.44%-51.98%-78.94%
20202.25%-7.49%-30.00%68.03%19.03%7.14%-0.00%-31.75%-2.33%-13.81%12.15%6.40%-2.70%
201913.71%-56.03%-3.71%-14.44%-19.08%-27.14%17.65%-21.50%3.61%6.97%-3.07%-12.25%-78.86%
201820.00%-14.17%-11.51%2.19%13.50%-3.38%-12.87%-10.91%-14.23%-7.56%-24.09%-37.13%-70.00%
20170.23%112.79%30.50%7.67%-1.40%-11.72%-7.94%18.33%-9.45%16.98%-10.11%-16.27%126.54%
20163,032.13%2.91%-8.89%-23.65%-3.44%2,065.17%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of QNRX is 22, meaning it’s performing worse than 78% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of QNRX is 2222
Overall Rank
The Sharpe Ratio Rank of QNRX is 2424
Sharpe Ratio Rank
The Sortino Ratio Rank of QNRX is 3030
Sortino Ratio Rank
The Omega Ratio Rank of QNRX is 3131
Omega Ratio Rank
The Calmar Ratio Rank of QNRX is 1212
Calmar Ratio Rank
The Martin Ratio Rank of QNRX is 1414
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Quoin Pharmaceuticals Ltd DRC (QNRX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Quoin Pharmaceuticals Ltd DRC Sharpe ratios as of May 28, 2025 (values are recalculated daily):

  • 1-Year: -0.47
  • 5-Year: -0.41
  • All Time: -0.05

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Quoin Pharmaceuticals Ltd DRC compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


Quoin Pharmaceuticals Ltd DRC doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Quoin Pharmaceuticals Ltd DRC. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Quoin Pharmaceuticals Ltd DRC was 100.00%, occurring on Apr 14, 2025. The portfolio has not yet recovered.

The current Quoin Pharmaceuticals Ltd DRC drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Sep 7, 20171911Apr 14, 2025
-49.81%Aug 2, 2016100Dec 21, 201614Jan 12, 2017114
-49.31%Jan 13, 201712Jan 31, 201710Feb 14, 201722
-34.37%May 24, 201756Aug 11, 201716Sep 5, 201772
-16.63%Apr 7, 201710Apr 21, 201712May 9, 201722
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Quoin Pharmaceuticals Ltd DRC over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Quoin Pharmaceuticals Ltd DRC, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -54.8%.


-350.00-300.00-250.00-200.00-150.00-100.00-50.000.0020212022202320242025
-6.50
-4.20
Actual
Estimate

Valuation

The Valuation section provides an overview of how Quoin Pharmaceuticals Ltd DRC is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for QNRX relative to other companies in the Biotechnology industry. Currently, QNRX has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for QNRX in comparison with other companies in the Biotechnology industry. Currently, QNRX has a P/B value of 0.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items